- Home
- RLAY vs PHAT Comparison
RLAY vs PHAT Comparison
Compare RLAY & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- PHAT
- Stock Information
- Founded
- RLAY 2015
- PHAT 2018
- Country
- RLAY United States
- PHAT United States
- Employees
- RLAY N/A
- PHAT N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- RLAY Health Care
- PHAT Health Care
- Exchange
- RLAY Nasdaq
- PHAT Nasdaq
- Market Cap
- RLAY 803.4M
- PHAT 835.7M
- IPO Year
- RLAY 2020
- PHAT 2019
- Fundamental
- Price
- RLAY $5.48
- PHAT $12.21
- Analyst Decision
- RLAY Strong Buy
- PHAT Strong Buy
- Analyst Count
- RLAY 8
- PHAT 5
- Target Price
- RLAY $17.25
- PHAT $16.40
- AVG Volume (30 Days)
- RLAY 1.6M
- PHAT 1.2M
- Earning Date
- RLAY 11-05-2025
- PHAT 11-06-2025
- Dividend Yield
- RLAY N/A
- PHAT N/A
- EPS Growth
- RLAY N/A
- PHAT N/A
- EPS
- RLAY N/A
- PHAT N/A
- Revenue
- RLAY $8,355,000.00
- PHAT $114,039,000.00
- Revenue This Year
- RLAY $27.33
- PHAT $213.11
- Revenue Next Year
- RLAY $8.87
- PHAT $91.84
- P/E Ratio
- RLAY N/A
- PHAT N/A
- Revenue Growth
- RLAY N/A
- PHAT 1049.82
- 52 Week Low
- RLAY $1.78
- PHAT $2.21
- 52 Week High
- RLAY $7.07
- PHAT $19.50
- Technical
- Relative Strength Index (RSI)
- RLAY 75.63
- PHAT 56.82
- Support Level
- RLAY $5.17
- PHAT $11.74
- Resistance Level
- RLAY $5.42
- PHAT $12.49
- Average True Range (ATR)
- RLAY 0.29
- PHAT 0.70
- MACD
- RLAY 0.08
- PHAT -0.02
- Stochastic Oscillator
- RLAY 95.97
- PHAT 78.02
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.